IS spravato the same as ketamine

If you have been researching treatment options for depression, especially treatment resistant depression, you may have come across two terms that sound almost identical: ketamine and Spravato.

Many people ask me the same question in my office: Is Spravato the same as ketamine?

The short answer is no. They are closely related, but they are not exactly the same. The differences matter, especially when it comes to safety, insurance coverage, effectiveness, and long term planning.

In this article, I will break-down the science in simple language so you can understand clearly and confidently.

What Is Ketamine?
Ketamine has been used in medicine since the 1970s. It was originally developed as an anesthetic, meaning it was used for surgery and emergency procedures. It is still used today in operating rooms and emergency departments.

Over the last twenty years, researchers discovered something surprising. At much lower doses than those used for anesthesia, ketamine can rapidly improve symptoms of severe depression.

Unlike traditional antidepressants that may take four to six weeks to work, ketamine can sometimes reduce depressive symptoms within hours to days. That discovery changed psychiatry!

What Is Spravato?
Spravato is a prescription nasal spray that contains a specific part of the ketamine molecule called esketamine.

Spravato was approved by the FDA in 2019 for adults with treatment resistant depression and later for major depressive disorder with suicidal thoughts.

It is given in a certified medical office under supervision. Patients self administer the nasal spray while medical staff monitor blood pressure and overall response for about two hours.

Spravato is not taken at home. It is part of a structured treatment program.

Racemic Mixture Versus Single Enantiomer
This is where things get scientific, but I will explain it in everyday terms.

Ketamine as it was originally developed is a racemic mixture. That means it contains two mirror image forms of the same molecule. These are called enantiomers.

Think of your hands. Your left and right hands are mirror images of each other. They look similar but are not identical.

Traditional ketamine contains both the left handed and right handed versions of the molecule mixed together.

Spravato contains only one of those mirror image forms. Specifically, it contains the S enantiomer called esketamine.

Why does this matter?
Research suggests that the S enantiomer may bind more strongly to certain brain receptors involved in mood regulation. By isolating this specific form, scientists created a more targeted medication.

So ketamine is both mirror images together. Spravato is just one mirror image purified and studied independently. This difference allowed Spravato to go through the full FDA approval process for depression.

How Do They Work in the Brain?
Both ketamine and Spravato affect a brain receptor called the NMDA receptor. This is part of the glutamate system, which plays a major role in mood, learning, and memory.

Most traditional antidepressants work on serotonin or norepinephrine. Ketamine and Spravato work differently.

They help stimulate new neural connections in areas of the brain involved in mood. Some researchers describe this as helping the brain form new pathways after being stuck in depressive patterns. This may explain why they can work more quickly than standard antidepressants.

Effectiveness
Both intravenous ketamine and Spravato have been shown to significantly reduce symptoms of depression, especially in people who have not responded to multiple antidepressants. Spravato went through large clinical trials before FDA approval. These trials showed that when combined with an oral antidepressant, Spravato improved depressive symptoms more than placebo.

Many patients report:
• Improved mood
• Reduced suicidal thoughts
• Increased motivation
• Greater emotional flexibility

No treatment works for everyone, but for individuals with treatment resistant depression, Spravato has become one of the most promising options available today.

Routes of Administration
​This is another major difference.
Ketamine for depression is most commonly given as:
• Intravenous infusion
• Intramuscular injection
• Sometimes oral or lozenge form

Spravato is given as:
• Nasal spray administered in a medical office

Each route has pros and cons.
Intravenous Ketamine Pros:
Precise dosing
Rapid onset
Strong research support

Cons
Not covered by insurance for depression
Higher out of pocket cost
Requires IV access

Oral or Lozenge Ketamine Pros
Convenience
Lower cost in some settings

Cons
Less predictable absorption
Not FDA approved for depression
Usually not covered by insurance

Spravato Nasal Spray Pros
FDA approved specifically for depression
Insurance coverage is common
Structured safety monitoring
Standardized dosing
Extensive research data

Cons
Must remain in clinic for observation
Requires transportation home after treatment

Insurance Coverage
This is a critical issue.

Spravato is FDA approved for treatment resistant depression. Due to this, most commercial insurance plans and many Medicare plans provide coverage for Spravato  when criteria are met.

Patients typically must:
• Have a diagnosis of major depressive disorder
• Have failed at least two antidepressants

Traditional ketamine infusions for depression are often considered off label. The vast majority of insurance companies do not cover them, which can lead to significant out of pocket expenses.

From a practical standpoint, Spravato is often more financially accessible.

Safety and Monitoring
Spravato is administered in a certified treatment center under a Risk Evaluation and Mitigation Strategy program required by the FDA.

Patients are monitored for:
• Blood pressure changes
• Sedation
• Dissociation
• Nausea

Most side effects occur during the observation period and resolve within a few hours.

Common side effects include:
• Dizziness
• Feeling disconnected
• Nausea
• Temporary increase in blood pressure

These effects are expected and usually manageable.

Common Contraindications
Spravato and ketamine are not appropriate for everyone.

They are typically avoided or used with caution in people with:
• Uncontrolled high blood pressure
• Aneurysms
• Certain vascular diseases
• History of psychosis
• Active substance misuse
• Pregnancy

A thorough psychiatric and medical evaluation is essential before starting treatment.

Is One Better Than the Other?
It depends on the situation.

Ketamine infusions may offer flexibility and individualized dosing. Cost and insurance barriers can limit access.

Spravato offers:
• FDA approval
• Standardized protocols
• Insurance coverage
• Structured safety oversight
• Extensive clinical trial data

For many patients, those factors provide reassurance and accessibility.

What Is the Treatment Experience Like?
Spravato treatment usually begins with twice weekly sessions for the first four weeks. After that, treatments gradually space out based on response.

Patients remain in a comfortable treatment room. Many listen to calming music or rest quietly during the observation period. You cannot drive the day of treatment. Most people feel back to baseline by the evening. Over a short time, many patients report that the “weight” of depression begins to lift.

A Positive Perspective
Depression can feel hopeless, especially when multiple medications have failed.
Spravato represents something different. It is based on a new understanding of how the brain regulates mood. It works faster than traditional antidepressants in many cases. It is supported by rigorous clinical research. It is covered by insurance for many patients.

It is not a miracle cure. It does not replace therapy or healthy lifestyle changes, but for individuals with treatment resistant depression, it can open a door that previously felt closed.

If you have struggled for years without meaningful relief, discussing Spravato with a qualified psychiatrist may be a worthwhile step.
​
You deserve options. You deserve hope. And modern psychiatry now offers more than ever before.